ArticlePilot and feasibility studies2026
FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.
Article in Pilot and feasibility studies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is an incurable plasma cell malignancy with relapses and diminishing response durations. Preclinical studies suggest that time-restricted eating (TRE)-related metabolic changes may enhance chemosensitivity by exploiting cancer cell vulnerabilities to nutrient deprivation. Clinical data in solid tumours remain limited and heterogeneous, mainly supporting feasibility and possible toxicity reduction rather than definitive efficacy. While efficacy has been explored in breast cancer patients, there is a lack of data for haematological patients, including MM. FASTINA (Fasting in Staging of MM - Intervention for Nutritional Adherence) will therefore primarily assess feasibility and safety and will explore preliminary efficacy of incorporating TRE into standard MM therapy. FASTINA is a single-centre, open-label, parallel-group randomised controlled feasibility trial (DRKS00034370). 54 adults with MM will be randomised 1:1 to either 16:8 TRE + nutritional counselling or nutritional counselling alone for 12 weeks during systemic therapy. Primary endpoints are adherence to the diet (adherence ≥ 80%) and complete response with measurable residual disease (MRD) negativity at treatment end. Secondary endpoints include response rates, nutritional status, body composition changes, frequency of ≥ grade 3 adverse events (AEs), progression-free (PFS) and exploratory overall survival (OS), quality of life (QoL), and fatigue. FASTINA will evaluate whether TRE is feasible and safe in selected MM patients and whether there is a hypothesis-generating signal for improved treatment response, informing the design of a subsequent phase II trial.Trial registration Deutsches Register Klinischer Studien (DRKS), DRKS00034370. Registered 21 June 2024, https://drks.de/search/de/trial/DRKS00034370 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.